and thank afternoon Good you for today. joining us
expected in digital differentiated launch while single existing pipeline a with promotional spatial transition scale beginning investors with our as highly company the our well in advancing platforms. small This execute as company profiling to employees. fully results our currently quarter requires to both third we is growth transforming on to opportunity our technology Our or XXXX. from platform disappointing drive were continue to programs multiple late which were NanoString of parallel that income scaled platform a
to am prepared growth near call for and our pipeline and our platform to close to and predictability recent driving over return my growth that over the factors Jim of first understand our believe factors stabilize on to of XXXX. objectives resolve nCounter volatility excited progress in the focus detailed results going operating While business the strategic remarks the nCounter these with have we of our plans I to returning business. assessment support course to both our third term in brief opportunities, to We our before a on action are quarter. them. our and our we by review our most turning for key taken and is priority the the I’ll today performance
Let me recapping briefly by our performance. start QX
and Our year-on-year. $XX.X was XX% million product down service revenue
source the instruments Our academic and of was business consumables. for primary both weakness
Panel consumables. decreased into Prosigna sciences year-over-year single would down playing role was million down Our year-on-year. revenue XX% and by orders with growth have a of Custom an in instrument reduced approximately million split flat approximately for bio-pharma consumable business and revenue $X that $X.X decline double-digit but CodeSet strong rate $XX.X was approximately from to customer. while Instrument grown revenue offset a academic customers in revenue weakness consumable at slipped QX. was was X% XX% revenue relatively a was sales important Total million, multiple as Life
customers customers. weeks, features nCounter. distinctive to few including quarter, last the the of our thorough trends dozens Over speak of they third When we in three we highlight a situational with analysis completed business interviews of
days ability speed, sample is first of insight publishable weeks. the instead The to go from to in
system their can run they simplicity; own data on bioinformaticians. the is second and an army The without their analyze of
made our companies, research publishing papers large X,XXX narrows many most. it of with such date. targets demand QX does are embraced that gene a technology. platform strength leader, where for to immuno-oncology our over believe our of technology not customers researchers Academic peer-reviewed the we performance or particularly however, areas is have clear for base expression nCounter third profiling, have biology pace of content; and they as their we our at reflect love Biopharma in The are choice the pre-design healthy satisfaction and our that small panels the
challenges impact identified what two, So taken circumstances, our they our factors evolving business commercial steps performance. these analysis, some we during on all factors a Based Through we happening? is we believe are execution, key our have spreads issue. dynamics. manageable each address three substantially already These of on to impact performance We believe the QX. have combine market factors of of that three impacted our are and confluence one; to in that and
Let our in commercial me challenges start with execution. the
marketing happen the have from reps marketing, during to we increase Senior a our and quarter and and leadership Vice wave to retrospect, new these of we leader we challenges change operations, this quarter. need become always in an in vast pace been have in substantial under of XX increased actions dedicated may challenging our earlier and the the President the commercial estimated address steps year decisive these commercial transition were This the As of our a sales activity reps appointment in consumables, to we time took taken including will former hired the last improve the execution XXXX of In July Brown. and the with field of tends take academic Veteran issues, early sector commercial and QX. quarter. new the Simultaneously, effective. execution based down organization year absorbing commercial inside of training identified second days to Chad a July, sales hiring August, in majority our reminder, lead In the slow our commercial Industry our is to new who substantial QX began activities. as the of to meaning and fully needs to risk to
that long are challenges in individuals us. these largely with leaders with positions run, consumable and or commercial leadership roles the QX. alumina effectiveness actions results from have changes like execution We while filled transitional the should behind these created may reduced dynamic QIAGEN. new Chad sales temporarily industry Our sales indicate and these believe has recruited inside improve during
generation lead entered with QX funnel are Our company and instrument efforts largest history. a in we accelerating
based reps our dedicated investment results. is showing addition, and consumable fuel In
We support indicators increasing. of of expect territories growth to are third commercial leading that by issued Other such the during encouraged are fact substantially consumable the field in North consumable help also the in in with sales reps sales those XXXX. size improve Overall, consumable number consumable and to quotes QX reps quarter. base growth and territories in American we outperformed without execution as
the sold. SPRINT cost and first our to attacks researchers which had privy as in in has is the factor growth impact of and accounts to encounter institutions penetrate of second not instruments them. where our quickly launched to low the installed XX% base accelerated XX% It The grew many of Profiler, XXXX July helped
has our each potential on are slipped forecasted beyond the our consumable By researches sound, with SPRINT believe were which QX. strategy relative While of we pulse less has new systems This number more visibility revenue the SPRINT core quarter that installed instrument happened individual on increased lower than they lengthened timing cycle increases system decreased. average SPRINT targeting certain compensated. to historical and instrument our the of for and outside By reduced has the MAX within our order visibility sales base, the as has instruments. oncology customers our and risk in business, the FLEX funding that of
forward. on recent strongest October the apply initiatives SPRINT its are increase October increase relative previous expectations. last appeal sales closed This our were size our developing We record for outside said, growth. of should of being to to That near revenue insights term in going to these revitalize funnel many our month and reduces forecast term, making we that accuracy encouraged the instrument the by panels Longer our during instrument orders. SPRINT oncology orders need to outlook broaden
Finally, let our consumable some that address impacting market evolving trends. me dynamics are
than purchased it’s The consumable XXX life Science Custom that customers that [Ph] sold Panel, and and revenue accept of have experiments are the and into access CodeSet selling are PanCancer premium has Since more our our from revenue expression reminder, that prices researches. priced at co-existed primary at majority to other our two worldwide. a Profiling science balance catalog curated platforms comes A number designed The products are – to by relative is in specifications other one customer of XXXX consumables formats. sell segment our panels. from Life a including of appeal launched example product which alongside large their genes broad been our As profiling is for genes sample intensive expression gene diagnostic that want to alternative experiments researchers test. these from identify nCounter times. on focussed known trying cover of complex a In to our RNA-Seq think important complimentary turnaround which all cases, which for an customers RNA-Seq transcriptome. when or slow more of to they on use bioinformatics, sequencing translate can and the when to Virtually importance. in Most in nCounter and all labor customers willing it Many biology gene attractive and a approaches. RNA-Seq a speed are panels to are good nCounter to consumable along approach in the insights prefer workflow, they to as technology insight of comes biological Immune carefully we runs
In our identified built a were that using custom of to Recently, RNA-Seq. has dynamic profile gene were emerged. designed many fact, a first market signatures diagnostic such and CodeSet new
which similar priced cost nCounter. there for cost RNA-Seq a on are of has using As whole for a is volume come to it some Custom lower CodeSet ordering applications transcriptome premium
experiments appears nCounter been our order our to an of existing CodeSet portion This of shifted Some RNA-Seq. by market primarily be Custom have of that dynamic performed would business. our have to impacting customers
cost immuno-oncology prepared sequencing products our business. use repeat with popular a panel research significant for Our panels something we’ve and for. and The following anticipated remained oncology including is of in endeavour PanCancer
We’re pursuing initiatives address this dynamics. three that will
related these should CodeSet allow our to First, we making to that projects. of are win policies our reps adjustments tactical Custom to some discounting more
channel and leveraging expanding win sales consumable are that Most back our yielding important the results. turnkey workflow business, are most most base increasing Second, volume these we and promising high strategy competitive our carefully on where introducing a our bioinformatics. importantly, pronounced. The our consumable advantages and are panels protect already to our of that’s strengthened on applications focus we simple curated research capitalize are
number targeting which and PCR have are that Separately, we low have expanded technologies. experiments our of plan our panels strong are products disciplines panel we over as next quarters. of panels start and a and the off spanning two practical such IOXXX numbers on traditionally not PlexSet to New with samples sequencing neurology quantitative lined applications large our genes of offering and to variety been launch multiple and for a
overtime, the clear expect the maintain and our trends consumable represented the In through our in of we business. summary, pull We understanding panels PlexSet share of that have nCounter revenues. will lion’s believe our of vitality a consumable we
the reflects performance business confluence stronger than QX fundamentals of we circumstances indicates. Our underlying believe and are our QX performance the
product to pipeline our update stabilize on XXXX. and of We I’ll to believe business strengthen close programs commercial have our longer the technologies. our us offerings, over and taken action on term focussing which return and we strategic an course improve QX decisive execution advancing in will growth diagnostic priorities the with
are the national During and the to driven sites to U.S. of by Most Prosigna and outside the increasing labs with XX% engagement we active year Prosigna adoption to QX, increased by continues payers. through Prosigna of XX Prosigna where be increased prior patient revenue access revenue regional our worldwide. steadily over number
Centers the updated Prosigna unexpected CMS Medicaid the late services from CMS. Medicare lab a along In with from September, an other or reschedule clinical of providers and multi we Within test face [ph] the preliminary challenge the U.S. crosswalk from published analytic the reimbursement if for advisory to reviewing reduce the a was recommendation XXXX. implemented which under contrary the Prosigna CPT for This would the decision panel the in of determination decision. [Indiscernible] of substantially code of reimbursement
and comment proposed meet staff to comment the period have to with advantage We on CMS of taken the formally policy. the
our issue. in regaining our resolution I’d collaborations. our some are developments and to ongoing also successful by like share encouraged to look biopharma We to discussions this forward
Celgene analysis. completed and trial in First, following has those is primary now patients enrolment toward event driven robust the an
Large studies growing subtyping We lymphoma different Lymphoma in for be the the the for will a continue is the to Meanwhile research. collaboration Annual being test in XX Diffuse Celgene be basis biomarker of will American Meeting follow XXXX. of Haematology expect for algorithm at use an which demonstrating in in presented subject base the December, in position to Society assay’s encounter REVLIMID test that B-Cell since PMA
we as for data October, our longer commercialization not late or for In of obviously is development Tumor collaboration. to patients our the was impact do decision of notified team, this The Merck TIS the our is for Signature, a no Inflammation were required by end no select companion their our longer to to these disappointing We understand Turning Phase Keytruda its diagnostic to or its in This that tumor our diagnostic. we believe of Merck on TIS, complimentary to a development yield TIS that interim as but current filing Merck our Merck and collaboration based X the of Merck’s that with indications. this support represents those of expect we TIS decision trial types. was for work PMA that not or basket the diagnose and keynote Keytruda. from but XXX from conclusion analysis decision basket
in relationship up collaboration various to Our our coordinating few related determine Merck to types. parallel cancer research of in look remained next to future gene our in TIS interest over Merck potential on existing signatures months; forward collaboration immune potential utility strong ongoing shared lap discussions with to expression the with activities we the and
shipping to XX diagnostic While have future and field the more remains information Merck any on The the companies. new last expansion continuing different biopharma to call, Panel positively our quarter. number immuno-oncology agreement are XX in a degree collaborations. QX provides in panel, other XX% approach and immune Immune with related we response. collaboration, become dialogue XX% IO program researchers described September the of open In year-to-date. extend the engagement biopharma our and have a responded that has non-pilot in a already up with pilot constructive have we to in That were Meanwhile, of biopharma the helping through studies studies fastest tumor in we the and Profiling researchers tumor, single potential and academic the researchers tool number pilot our reached powerful with in with our any of dynamic. companies. studies began XXX and of expand our environment potential Sales new Under leadership of not the parallel, launch that view to micro our we of focus of signature our are PanCancer late XXX up executed
the field continuing panel. will organization our Institute, we with an who the will NSABP. partner a the Cancer combinations. will which Society where abstracts be is will colorectal collaboration including IO an XXX order immunotherapies IO abstracts that collaboration an current NSABP next we This panel the than industry analyze instance, conference identifying to from a in week which leadership of to XXX last bank the future on announced week patients For panel NSABP's part five we in for use with our and more And foundation, to display cancer highlighting phenotypes important honoured characterise and presented record academic research to by being at of our supported of bio XXXX cancer This is tumor have of Immuno-therapy In step immuno National benefit is cancer. of immuno-oncology samples. are
Finally, quarter, advancing made our of new during third we in the technology portfolio platforms. progress
our We meetings. technology profiling presenting date. launch the in market presented we on At customers abstracts of are by [Indiscernible] building the the spatial we’ll data three continuing access now platform, are abstracts, plan meeting DSP by next at year engaging just to our XX away one to program major develop present week, from digital the
academic XX now XX Our companies including includes biopharma with than with researchers. XX government and program and expanded more technology access projects
technical announced have demand a the cancer which believe made into to accelerate $XX up our million centers in on that On entered off partnership equity and follow royalty to valuable this that and Currently, quarter. will interest projects and disruptive I’m one advanced We strategic track. Under Hyb Lam collaboration Lam Xth to and strong have full rights partner. Lam synergies we Research agreement Lam quickly with the that do this option Hyb in on researchers Hyb in an on return during of a pharma our a is clear invaluable this back DSP clinical the development well sign their August leaving terms has indicator and retains commercial you a of chemistry a for with & Seq own been a to nanoscale NanoString. is the in We’ve had believe expectations. speed & Research be us exceeded Seq great leading also Hyb expertise of team & sales the to on is development have collaboration on NanoString have the engineering great nation’s fantastic leading development the come great It's to and Seq expanding sequencer will premier which commercialize provide technology. powerful differentiated third going companies progress start. to find tell the for The that teams technology. pleased data the of to of manufacturing program we with or be optimizing & we to we The identified what fund progress Seq. will and remains
The promising cell-free sample of blood clinical addressable about competitive for in expected $XX by durable the platforms pipeline biopsy report and rapidly results the that a advantage. Scottsdale is Precision Health for principal streams progress The In XXXX we next significantly work become in February. AGBT in of in an XXXX. report from new These this simple will workflow presented total revenue Our the annual major financial biopsy a DNA of launch is September, like and Meeting these and at drivers has planned the also to sequencing hour. tool revenue instrument circulating opportunity sequencing over growing call Seq in Jim expand cell-free estimated to programs Hyb that, non-invasive provide & DNA our XXXX With to oncology exciting potential major liquid to in market Arizona. I’d to proof market be liquid have in initiate to guidance. AGBT beyond. billion are hand is of update
